ESCITALOPRAM-ACTAVIS

UNIVADIS - ESCITALOPRAM-ACTAVIS /univadis/ESCITALOPRAM-ACTAVIS.md

ATC

Μορφές: F.C.TAB

Δραστικές

Δελτίο Τιμών 05/2018

Ημερομηνία barcode code περιεχομενο τιμή παραγωγός χονδρική λιανική
05/2018 2802810702031 281070203 ESCITALOPRAM/ACTAVIS F.C.TAB 10MG/TAB BT x 28 5.40 5.66 7.80
05/2018 2802810704035 281070403 ESCITALOPRAM/ACTAVIS F.C.TAB 20MG/TAB BT x 28 9.57 10.04 13.83
  • DRUGBANK - Escitalopram
  • indication:

    For the treatment of major depressive disorder and Generalized Anxiety Disorder (GAD).

  • pharmacology:

  • mechanism:

    The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.

  • toxicity:

    Signs of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).

  • absorprion:

    The absolute bioavailability of citalopram is about 80% relative to an intravenous dose

  • halflife:

    27-32 hours

  • roouteelimination:

    Following oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).

  • volumedistribution:

    * 12 L/kg

  • clearance:

    * oral cl=600 mL/min [Following oral administrations]